Keywords: Bristol-Myers Squibb, Nulojix, Kidney transplant, European Commission
Bristol-Myers Squibb gets EU approval for Nulojix for kidney transplant rejection
Article | 21 June 2011
The European Commission yesterday granted marketing authorization for US drug major Bristol-Myers Squibb’s (NYSE: BMY) Nulojix (belatacept), a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
